For research use only. Not for therapeutic Use.
Goflikicept (RPH 104) is a hybrid protein that selectively binds and inactivates both circulating IL-1ß and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI)[1].
| Catalog Number | I041847 |
| CAS Number | 2416984-26-2 |
| Purity | ≥95% |
| Reference | [1]. Samsonov M, et al. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med. 2021 Apr 26;19(1):169. |
